News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|April 20, 2022

Educating on RWE

Dr Richter delves into how we can better educate patients and physicians on RWE to improve decision-making.

Episodes in this series

multiple myeloma

EP. 1 Coming Soon: Real-World Evidence in the Evolving Treatment Landscape of Multiple Myeloma

EP. 2 A Multiple Myeloma Overview

EP. 2 A Multiple Myeloma Overview

EP. 3 MM and Regimens for First- and Second-Line Treatment

EP. 3 MM and Regimens for First- and Second-Line Treatment

EP. 4 MM From the Payers’ Perspective

EP. 4 MM From the Payers’ Perspective

EP. 5 MM Healthcare Resource Utilization

EP. 5 MM Healthcare Resource Utilization

EP. 6 Decision Support Tools for MM

EP. 6 Decision Support Tools for MM

EP. 7 MM and the Limitations of RCT Data

EP. 7 MM and the Limitations of RCT Data

EP. 8 MM and Real-World Evidence

EP. 8 MM and Real-World Evidence

EP. 9 The Value of RWE in MM

EP. 9 The Value of RWE in MM

EP. 10 Incorporating RWE in MM Decision-Making

EP. 10 Incorporating RWE in MM Decision-Making

EP. 11 RWE Decision-Making Barriers

EP. 11 RWE Decision-Making Barriers

EP. 12 MM and Non-Comparative RWE

EP. 12 MM and Non-Comparative RWE

EP. 13 Educating on RWE

EP. 13 Educating on RWE

EP. 14 MM Unmet Needs

EP. 14 MM Unmet Needs

EP. 15 Incorporating RWE Into Future Decision-Making

EP. 15 Incorporating RWE Into Future Decision-Making

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Zobair M. Younossi, MD

Lifestyle Factors Offer Actionable Targets in MASLD Management: Zobair M. Younossi, MD

ByBrooke McCormick,Zobair M. Younossi, MD,Laura Joszt, MA

August 16th 2026

soft tissue sarcoma image | Image credit: Dr_Microbe - stock.adobe.com

Sarcoma Gene Signature May Predict Who Benefits From Pazopanib

ByLaura Joszt, MA

August 16th 2026

Matthew A. Lunning, DO, FACP, discussed the prospects for use of bispecifics following R-CHOP in DLBCL in a recent interview. | Image: University of Nebraska College of Medicine

Lunning Sees Use of Bispecifics in Consolidation Phase in DBLCL

August 14th 2026

Retatrutide injection pen — Eli Lilly's investigational triple agonist GLP-1 drug | Image credit: Anna Hoychuk - stock.adobe.com

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

ByPearl Steinzor

August 14th 2026

Lidia Schapira, MD

Adapting Breast Cancer Therapy to the Individual, Not Just the Scan: Lidia Schapira, MD

ByGiuliana Grossi,Lidia Schapira, MD, FASCO

August 14th 2026

Trending on AJMC

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care

Sarcoma Gene Signature May Predict Who Benefits From Pazopanib

Lifestyle Factors Offer Actionable Targets in MASLD Management: Zobair M. Younossi, MD